Pricing Log in Create free account
Saturday 17 October 2026 Export RDGT’s income statement to Excel — free account

Ridgetech Inc.

RDGT Healthcare Pharmaceutical Retailers

Ridgetech Inc.’s revenue for fiscal 2026 (year ended March 2026) was $132.2 million, up 10.2% from fiscal 2025. Insiders bought in the last twelve months.

0.84 0.01 +1.20%
Market cap
$3.0M
P/E
0.0×
Fwd P/E
−5.6×
Dividend yield
—
F-score
4/9
Altman Z
1.16
Beneish M
−2.32
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.16
Total sells 0.12
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — 3 — — — —
Sell — — — — — — — 3 — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 3.01
Revenue 313.20
Net Income (8.05)
Free Cash Flow 10.76
Net Debt (18.05)
Current Ratio 1.82 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (5.60) (negative: loss-making)
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth 13.36% (at or above 10%: strong)
Next 5Y EPS Growth 30.00% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.0×, against a ten-year median of 0.0×; over the ten years it ranged from −0.1× in 2022 to 0.5× in 2019.

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 32 4 19 18
Receivables 17 6 30 38
Inventory 15 9 10 8
Other 1 0 1 0
64 70 60 65
2023 2024 2025 2026
Payables 27 31 20 23
ST’ Debt — — — —
Other 3 0 0 0
67 74 34 28

Compound Annual Growth %

10y 5y 3y
Sales 4.03% (0.15%) (3.88%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 7.76% 10.81% 31.30%

Revenue $m

Jun Sep Dec Mar Year
’26 — — — — —
’26 — — — — 132
’25 — — — — 120
’24 — — — — 124
’23 — — — — 149
’22 — — — — 164
’21 31 31 36 36 133
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 — — — — —
’26 — 5 — — (1)
’25 — — — — 1
’24 — — — — (3)
’23 — — — — (3)
’22 — — — — (5)
’21 (5) 5 (12) 12 0
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 — — — — —
’26 — 5 — — (1)
’25 — — — — 1
’24 — — — — (4)
’23 — 1 — (4) (3)
’22 — 0 — (6) (5)
’21 (6) 5 (12) 12 (1)
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 — — — — —
’26 — — — — (17.21)
’25 — — — — 274.63
’24 — — — — (437.31)
’23 — — — — (2.07)
’22 — — — — (11.01)
’21 (358.35) (1.43k) (5.38k) 0.00 (7.17k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 42,120.00 42,120.00 36,360.00 28,800.00 12,600.00 4,290.00 510.00 201.00 108.00 0.67

Analyst estimates 2027–2029

Powerpack
High 78,480.00 88,560.00 122,040.00 124,560.00 60,480.00 23,730.00 28,950.00 720.00 760.50 702.00
People
People Employees 893 1,139 1,079 1,074 1,047 — — — 61 64
Revenue/emp, $m 0.09 0.08 0.10 0.11 0.13 0.00 0.00 0.00 1.97 2.07
Income, $m
Income, $m Revenue 81 96 108 117 133 164 149 124 120 132
Gross margin, % 20.40 20.94 23.35 21.76 21.97 22.21 23.04 3.93 3.20 3.60
EBT (6) (17) (1) (6) (8) (2) (21) (1) (1) (1)
EBT margin, % (6.82) (17.67) (1.10) (5.49) (6.27) (1.28) (13.94) (0.67) (0.79) (1.02)
Net income (6) (17) (1) (6) (8) (3) (21) (4) 10 (1)
Depreciation 1 1 2 2 2 1 1 5 6 0
Per share, $
Per share, $ Revenue 135,831.83 137,303.86 134,438.75 130,364.11 121,031.45 567.07 14.59 12,782.90 3,242.48 1,817.93
Earnings (10,033.86) (24,367.96) (1,075.06) (6,450.34) (7,167.05) (11.01) (2.07) (437.31) 274.63 (17.21)
Cash flow 2,599.17 (2,957.29) (7,004.00) (7,675.44) (56.64) (18.58) (0.32) (325.30) 33.72 (19.17)
Capex (685.33) (4,145.71) (9,136.37) (2,537.56) (549.27) 0.00 0.00 (95.23) (16.63) (0.01)
Free cash flow 1,913.83 (7,103.00) (16,140.37) (10,213.00) (605.91) (18.58) (0.32) (420.53) 17.09 (19.18)
Book value 44,440.67 26,946.29 21,214.00 20,864.56 22,184.00 83.08 1.77 1,473.52 800.98 560.89
Shares, m 0 0 0 0 0 0 10 0 0 0
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.48 0.34 0.76 0.50 0.33 0.05 0.05 0.00 0.00 0.00
P/B 1.46 1.75 4.82 3.12 1.82 0.53 0.82 0.03 0.01 0.00
EV/Sales 0.14 0.02 0.53 0.29 0.11 (0.08) (0.04) (0.08) (0.09) (0.04)
EV/FCF 9.76 (0.23) (4.00) (3.69) (21.06) 3.25 1.34 2.89 2.93 (1.33)
Cash, $m
Cash, $m Operating cash flow 2 (2) (6) (7) 0 (5) (3) (3) 1 (1)
Capex 0 (3) (7) (2) (1) 0 0 (1) (1) 0
Free cash flow 1 (5) (13) (9) (1) (5) (3) (4) 1 (1)
Balance, $m
Balance, $m Working capital 16 8 1 4 7 1 (2) (5) 25 37
Total debt 13 19 26 6 4 49 42 — — —
Net debt (15) (12) 1 (25) (30) (35) (32) (4) (19) (18)
Shareholders’ equity 27 19 17 19 24 24 18 14 30 41
Returns, %
Returns, % ROA (8.73) (24.20) (1.26) (6.75) (7.89) (3.00) (21.42) (4.55) 12.78 (1.87)
ROIC (21.69) (160.14) (3.04) 0.00 0.00 0.00 0.00 3.72 (5.83) (5.10)
ROE (24.55) (74.94) (5.17) (32.52) (37.61) (13.17) (100.42) (26.21) 46.41 (3.55)
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Mar 2021

Charts ten years each

Ridgetech Inc. vs peers in Pharmaceutical Retailers (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HITI High Tide Inc. $228.2M — (loss-making) 92.0× +30.72% (above 0%: growing) +800.00% (above 0%: growing) −7.91% (below 0%: shrinking) 26.53% 4.38% Compare
PETS PetMed Express, Inc. $26.4M — (loss-making) 24.0× −19.86% (below 0%: shrinking) n/m +38.60% (above 0%: growing) 27.63% (15.19%) Compare
MEDS DataMeds AI, Inc $12.8M — (loss-making) — −77.15% (below 0%: shrinking) n/m −41.85% (below 0%: shrinking) 10.24% (412.67%) Compare
SCNX Scienture Holdings, Inc. $5.6M — (loss-making) — (loss-making) +3,235.92% (above 0%: growing) n/m −53.98% (below 0%: shrinking) 97.73% (785.71%) Compare
POM Pomdoctor Limited - Sponsored ADR $5.0M — — — — — — — Compare
RDGT Ridgetech Inc. $3.0M — (loss-making) — (loss-making) +113.14% (above 0%: growing) n/m +4,848.31% (above 0%: growing) 22.81% 0.00%
MDVLQ MedAvail Holdings, Inc. $2.9M — (loss-making) — (loss-making) −25.41% (below 0%: shrinking) n/m +66.32% (above 0%: growing) 43.95% (1,099.75%) Compare
BIMI BIMI Holdings Inc. $170.0K — (loss-making) — −48.85% (below 0%: shrinking) n/m +28.06% (above 0%: growing) 4.57% (124.83%) Compare
Median of peers $5.6M — — −22.63% — +10.08% 27.08% (268.75%)

All 8 Pharmaceutical Retailers stocks →

Ridgetech Inc. (RDGT) key facts

  • Strength: Ridgetech Inc.’s revenue for fiscal 2026 (year ended March 2026) was $132.2 million, up 10.2% from fiscal 2025.
  • Ridgetech Inc. (RDGT) is a Pharmaceutical Retailers company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, RDGT traded at $0.84, a market capitalization of $3.0 million.
  • Return on equity was −3.55% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.16 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Ridgetech Inc. (RDGT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/RDGT · Data as of Mar 31, 2021 · For information only; not investment advice. · © 2026 stockrow.com